Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer

Breast

Volumn 16, Issue 1, 2007, Pages 73-80

  Torrisi, Rosalba ^a   Colleoni, Marco ^a   Veronesi, Paolo ^a   Rocca, Andrea ^a   Peruzzotti, Giulia ^a   Severi, Gianluca ^a   Medici, Marta ^a   Renne, Giuseppe ^a   Intra, Mattia ^a   Luini, Alberto ^a   Nolè, Franco ^a   Viale, Giuseppe ^a   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Chemoendocrine primary treatment; Hormone receptor positive breast cancer; Premenopause

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTRADIOL; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN DERIVATIVE; GONADOTROPIN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGE; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER STAGING; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; MASTECTOMY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; PREMENOPAUSE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 33846640084     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2006.06.005     Document Type: Article

References (32)

1. Kaufmann M., Hortobagyi G., Goldhirsch A., Scholl S., Makris A., Valagussa P., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24 (2006) 1940-1949
2. Colleoni M., Minchella I., Mazzarol G., Nolè F., Peruzzotti G., Rocca A., et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 11 (2000) 1-3
3. Colleoni M., Viale G., Zahrieh D., Pruneri G., Gentilini O., Veronesi P., et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10 (2004) 6622-6628
4. Eiermann W., Paepke S., Appfelstaedt J., Llombart-Cussac A., Eremin J., Vinholes J., et al. Letrozole Neo-Adjuvant Breast Cancer Study Group: preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12 (2001) 1527-1532
5. Dixon J.M., Renshaw L., Bellamy C., Stuart M., Hoctin-Boes G., and Miller W.R. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 6 (2001) 2229-2235
6. Mansi J.L., Smith I.E., Wlash G., A'Hern R.P., Harmer C.I., Sinnett H.D., et al. Primary medical therapy for operable breast cancer. Eur J Cancer Clin Oncol 25 (1989) 1623-1627
7. Smith I.E., Walsh G., Jones A., Prendiville J., Johnston S., Gusterson B., et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13 (1995) 424-429
8. Smith I.E., A'Hern R.P., Coombes G.A., Howell A., Ebbs S.R., Hickish T.F., et al. TOPIC Trial Group. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 15 (2004) 751-758
9. Sataloff D.M., Mason B.A., Prestipino A.J., Seinige U.L., Lieber C.P., and Baloch Z. Pathological response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180 (1995) 297-304
10. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21 (2003) 3357-3365
11. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98 (2001) 10869-10874
12. Gruvberger S., Ringner M., Chen Y., Panavally S., Saal L.H., Borg A., et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 15 (2001) 5979-5984
13. Untch M., Kahlert S., Moebus V., Thomssen C., Muck B., von Bismarck F., et al., for the AGO Breast Cancer Study Group. Negative steroid receptors are a good predictor for response to preoperative chemotherapy in breast cancer-results of a randomized trial. Proc Am Soc of Clin Oncol 22 (2003) abstract 35
14. Harvey J.M., Clark G.M., Osborne K.I., and Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17 (1999) 1474-1481
15. Bear H.D., Anderson S., Brown A., Smith R., Mamounas E.P., Fisher B., et al., National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21 (2003) 4165-4174
16. Smith I.C., Heys S.D., Hutcheon A.W., Miller I.D., Payne S., Gilbert F.J., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20 (2002) 1456-1466
17. Gianni L., Baselga J., Eiermnann W., Guillem Porta V., Semiglazov V., Lluch A., et al., for the ECTO Study Group. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 11 (2005) 8715-8721
18. Semiglazov V.F., Semiglazov V., Ivanov V., Bozhok A., Ziltsova E., Paltuen R., et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER positive breast cancer. Proc Am Soc Clin Oncol 23 (2004) 7s (abstract 517)
19. Gazet J.-C., Ford H.T., Gray R., McConkey C., Sutcliffe R., Quilliam J., et al. Estrogen-receptor directed neoadjuvant therapy for breast cancer: results of a randomized trial using formestane and methotrexate, mitozantrone and mytomicin C (MMM) chemotherapy. Ann Oncol 12 (2001) 685-691
20. Miller W.R., Anderson T.J., Hawkins R.A., Keen J., and Dixon J.M. Neoadjuvant endocrine treatment: the Edinburgh experience. In: Dowsett M., and Howell A. (Eds). Primary medical therapy for breast cancer: clinical and biological aspects (1999), Elsevier, Amsterdam 89-99
21. Von Minckwitz G., Costa S.D., Raab G., Blohmer J.U., Eidtmann H., Hilfrich J., et al. Dose-dense doxorubicin, docetaxel and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled open phase IIb study. J Clin Oncol 19 (2001) 3506-3515
22. Bottini A., Berruti A., Brizzi M.O., Bersiga A., Generali D., Allevi G., et al. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. Endocr Relat Cancer 12 (2005) 383-392
23. Albain K.S., Green S.J., Ravdin P.M., Cobau C.D., Levine E.G., Ingle J.N., et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent. Initial results from Intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 21 (2000) 37a (abstract 143)
24. Kaufman M., von Minckwitz G., Smith R., Valero V., Gianni L., Eiermann W., et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21 (2003) 2600-2608
25. Krus S., Naor Z., and Seger R. Intracellular signalling pathway mediated by the gonadotropin-releasing hormone (GnRH) receptor. Arch Med Res 32 (2001) 499-509
26. Mangia A., Tommasi S., Reshkin S.J., Simone G., Stea B., Schittulli F., et al. Gonadotropin releasing hormone receptor expression in primary breast cancer comparison of immunohistochemical, radioligand and Western blot analyses. Oncol Rep 9 (2002) 1127-1132
27. Lippman M.E., Cassidy J., Wesley M., and Young R.C. Increasing the response rate to cytotoxic chemotherapy by endocrine means. J Steroid Biochem 23 (1985) 1173-1180
28. Conte P.F., Gardin G., Pronzato P., Miglietta L., Rosso R., Amadori D., et al. In vivo manipulation of human breast cancer growth by estrogens and growth hormone: kinetic and clinical results. J Steroid Biochem Mol Biol 37 (1990) 1103-1108
29. Bajo A.M., Schally A.V., Halmos G., and Nagy A. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res 9 (2003) 3742-3748
30. Ohta H., Sakamoto H., and Sath K. In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on cancer cell sensitivity to cis-platinum. Cancer Lett 134 (1998) 111-118
31. Recchia F., Sica G., De Filippis S., Saggio G., Di Blasio A., Cesta A., et al. LH-RH analogues as ovarian protection during adjuvant chemotherapy of premenopausal breast cancer patients. Breast Cancer Res Treat (2003) (abstract 146)
32. Del Mastro L., Catzeddu T., Boni L., Bell C., Sertoli M.R., Bighin C., et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 17 (2006) 74-78